In This Section

Program

FRIDAY, OCTOBER 16, 2020

OPENING REMARKS AND OPENING KEYNOTES
5-7:00 P.M.

A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, CA

OPening Reception
7-9:00 p.m.

Saturday, October 17, 2020

Continental Breakfast
7-8:00 a.m.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
8-10:00 AM         

Engineering artificial Antigen Presenting Complexes, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, MD

Title to be announced
Pamela A. Silver, Harvard Medical School, Boston, MA

 Additional speaker to be announced

BreaK
10-10:30 a.m.
Plenary Session 2: Vaccines, Neoantigens, and Oncolytic Viruses
10:30 AM-12:30 PM      

Building improved personal cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

Title to be announced
Adrian Hill, Jenner Institute at Oxford University, Oxford, England

Additional speaker to be announced

Poster Session A/Lunch
12:30-3: p.m.
NetWorking event
3-4:00 p.m.

Timothy A. Chan, Memorial Sloan Kettering Cancer Center, New York, NY

Keynote 3
4-5:00 p.m.

Speaker to be announced

Evening on own
5:00 p.m.

Sunday, October 18, 2020

Continental Breakfast
7-8:00 a.m.
Plenary Session 3: t-cell therapies
8-10:00 a.m.

Title to be announced
Marcela V. Maus, Massachusetts General Hospital, Boston, MA

Title to be announced
Avery D. Posey, University of Pennsylvania, Philadelphia, PA

Additional speaker to be announced

Break
10-10:30 a.m.
Plenary Session 4: Non-T-Cell Therapies
10:30 a.m.-12:30 p.m.

Title to be announced
Adrian C. Hayday, The Francis Crick Institute, London, England

Title to be announced
Judith Agudo, Dana-Farber Cancer Institute, Boston, MA

Additional speaker to be announced

Lunch on Own
12:30-2:30 p.m.
Plenary Session 5: Novel Combinations
2:30-4:30 p.m.

Title to be announced
Charles G. Drake, Columbia University Irving Medical Center, New York, NY

Additional speakers to be announced

Poster Session B/Reception
4:30-7 p.m.

Monday, October 19, 2020

Continental Breakfast
7-8:00 a.m.
Plenary Session 6: Innate and Adaptive Checkpoints
8-10:00 a.m.

 Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, CA

Additional speakers to be announced

Break
10-10:30 a.m.
Plenary Session 7: Defining Novel Immunotherapy Targets
10:30 a.m.-12:30 p.m.

Probing the immune system in cancer
Stephen J. Elledge, Harvard Medical School, Boston, MA

Title to be announced
Arlene H. Sharpe, Harvard Medical School, Boston, MA

Title to be announced
Peter A. Sims, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

Closing remarks
12:30